Bristol James Arthur

SEC source: 0001493152-26-041137 · ownership.xml · derivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,083

Underlying: Common Stock · 5,083 shares

Expires 2036-08-31

F2 · derivative.exercise_date: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

SEC source: 0001493152-26-041137 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,320

Underlying: Common Stock · 8,320 shares

Expires 2036-08-31

F1 · derivative.exercise_date: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

SEC source: 0001193125-26-288902 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,888

Underlying: Common Stock · 29,888 shares

Expires 2036-06-26

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001193125-26-001611 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,762

Underlying: Common Stock · 37,762 shares

Expires 2036-01-01

F1 · security: At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2026 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2026.

F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date.

SEC source: 0000950170-25-090418 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2035-06-23

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001493152-25-005720 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,074

Underlying: Common Stock · 72,074 shares

Expires 2035-02-07

F1 · derivative.exercise_date: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

SEC source: 0000950170-25-000630 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,678

Underlying: Common Stock · 45,678 shares

Expires 2035-01-01

F1 · security: At the election of the filing person the option grant was issued in lieu of the cash compensation payable to such person in 2025 in connection with each position on the issuer's board of directors and its committees for which such person is anticipated to serve in 2025.

F2 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12 increments beginning one month from the date of grant, subject to such person continuing to serve on the issuer's board of directors through the applicable vesting date.

SEC source: 0001209191-24-005920 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 20, 2025, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 6

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 5

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 18,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 9,570 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 67,494 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0000950170-24-072206 · ownership.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Bristol Survivor's Trust

Disclosed balance after: 0

Underlying: Common Stock · 22,150 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

SEC source: 0001140361-24-023011 · form4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,525

Underlying: Common Stock · 124,525 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock option shall vest as to 100% of the number of shares subject to the stock option on the one-year anniversary of the grant date.

SEC source: 0001209191-24-000272 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,747

Underlying: Common Stock · 62,747 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments beginning one month from the date of grant, subject to such person's continuing in service on the board through the applicable vesting date.

F2 · derivative.underlying_shares: At the election of the filing person, the option grant was issued in lieu of direct cash compensation payable to such person in 2024 in connection with each position on the board and its committees for which such person is anticipated to serve in 2024.

SEC source: 0001209191-23-039582 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2024, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-23-039331 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-20

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 21, 2024, subject to continued service through such date.

SEC source: 0001209191-22-062536 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bristol Survivor?s Trust, Dated October 26, 2019

Disclosed balance after: 20,000

F1 · ownership.nature: The securities reported herein as being purchased were purchased by the Bristol Survivor's Trust Dated October 26, 2019. Such securities may be deemed to be beneficially owned by the Reporting Person, who is the trustee of the Bristol Survivor's Trust Dated October 26, 2019.

SEC source: 0001209191-22-039199 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,500

Underlying: Common Stock · 18,500 shares

Expires 2032-06-22

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2023, subject to continued service through such date.

SEC source: 0001209191-22-039101 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 100% of the options to purchase shares vest on June 22, 2023, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

SEC source: 0001209191-22-004086 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,570

Underlying: Common Stock · 9,570 shares

Expires 2032-01-17

F1 · price: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee of $50,000 for the FY 2022 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. 2,393 shares will vest on March 31, 2022, 2,393 shares will vest on June 30, 2022, 2,393 shares will vest on September 30, 2022 and the remaining 2,391 shares will vest on December 31, 2022.

SEC source: 0001209191-21-043273 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2031-06-22

F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2022, subject to continued service through such date.

SEC source: 0001209191-21-027789 · doc4.xml · derivative · entry 7

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,150

Underlying: Common Stock · 1,700 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable as of July 31, 2020.

SEC source: 0001209191-21-027789 · doc4.xml · nonDerivative · entry 5

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.53 to $45.735, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-027789 · doc4.xml · nonDerivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-027789 · doc4.xml · derivative · entry 6

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,850

Underlying: Common Stock · 5,300 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable as of July 31, 2020.

SEC source: 0001209191-21-027789 · doc4.xml · nonDerivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.03, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-027789 · doc4.xml · nonDerivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.48, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-027789 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-026633 · doc4.xml · derivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,150

Underlying: Common Stock · 14,700 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable as of July 31, 2020.

SEC source: 0001209191-21-026633 · doc4.xml · nonDerivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.01 to $44.36, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-026633 · doc4.xml · nonDerivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,217

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.01 to $44.00, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-026633 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,700

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-004246 · doc4.xml · derivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,850

Underlying: Common Stock · 7,000 shares

Expires 2026-09-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable as of July 31, 2020.

SEC source: 0001209191-21-004246 · doc4.xml · nonDerivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.86 to $51.35, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-004246 · doc4.xml · nonDerivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.68 to $50.65, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-21-004246 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-054633 · doc4.xml · derivative · entry 5

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,541 shares

Expires 2025-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.

SEC source: 0001209191-20-054633 · doc4.xml · nonDerivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.13 to $55.73, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-054633 · doc4.xml · nonDerivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.13 to $55.12, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-054633 · doc4.xml · nonDerivative · entry 2

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,171

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 5, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.10 to $54.05, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-054633 · doc4.xml · nonDerivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-042769 · doc4.xml · derivative · entry 1

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723

Underlying: Common Stock · 723 shares

Expires 2030-07-15

F1 · derivative.exercise_date: These options were issued upon election by the director to receive his cash board retainer fee for the second half of 2020 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy and 362 shares will vest on September 30, 2020 and 361 shares will vest on December 31, 2020, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company.

SEC source: 0001209191-20-042243 · doc4.xml · derivative · entry 8

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,541

Underlying: Common Stock · 7,217 shares

Expires 2025-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.

SEC source: 0001209191-20-042243 · doc4.xml · derivative · entry 7

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,324 shares

Expires 2025-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.

SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 6

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.94 to $57.19, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 5

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.92 to $56.90, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 4

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,130

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.90 to $55.85, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 3

Bristol James Arthur · CIK 0001715153 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,180

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.90 to $54.88, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.